These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35769081)

  • 1. Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.
    Detomas M; Altieri B; Deutschbein T; Fassnacht M; Dischinger U
    Front Endocrinol (Lausanne); 2022; 13():903545. PubMed ID: 35769081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients.
    Bonnet-Serrano F; Poirier J; Vaczlavik A; Laguillier-Morizot C; Blanchet B; Baron S; Guignat L; Bessiene L; Bricaire L; Groussin L; Assié G; Guibourdenche J; Bertherat J
    Eur J Endocrinol; 2022 Aug; 187(2):315-322. PubMed ID: 35699971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients.
    Daniel E; Aylwin S; Mustafa O; Ball S; Munir A; Boelaert K; Chortis V; Cuthbertson DJ; Daousi C; Rajeev SP; Davis J; Cheer K; Drake W; Gunganah K; Grossman A; Gurnell M; Powlson AS; Karavitaki N; Huguet I; Kearney T; Mohit K; Meeran K; Hill N; Rees A; Lansdown AJ; Trainer PJ; Minder AE; Newell-Price J
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4146-54. PubMed ID: 26353009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.
    Fleseriu M; Pivonello R; Young J; Hamrahian AH; Molitch ME; Shimizu C; Tanaka T; Shimatsu A; White T; Hilliard A; Tian C; Sauter N; Biller BM; Bertagna X
    Pituitary; 2016 Apr; 19(2):138-48. PubMed ID: 26542280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
    Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
    Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metyrapone treatment in Cushing's syndrome: a real-life study.
    Ceccato F; Zilio M; Barbot M; Albiger N; Antonelli G; Plebani M; Watutantrige-Fernando S; Sabbadin C; Boscaro M; Scaroni C
    Endocrine; 2018 Dec; 62(3):701-711. PubMed ID: 30014438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
    Varlamov EV; Han AJ; Fleseriu M
    Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.
    Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3437-3449. PubMed ID: 31127821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France.
    Dormoy A; Haissaguerre M; Vitellius G; Do Cao C; Geslot A; Drui D; Lasolle H; Vieira-Pinto O; Salenave S; François M; Puerto M; Boullay HD; Mayer A; Rod A; Laurent C; Chanson P; Reznik Y; Castinetti F; Chabre O; Baudin E; Raverot G; Tabarin A; Young J
    J Clin Endocrinol Metab; 2023 May; 108(6):1475-1487. PubMed ID: 36470583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
    Perosevic M; Tritos NA
    Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome.
    Verhelst JA; Trainer PJ; Howlett TA; Perry L; Rees LH; Grossman AB; Wass JA; Besser GM
    Clin Endocrinol (Oxf); 1991 Aug; 35(2):169-78. PubMed ID: 1657460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples.
    Fleseriu M; Biller BMK
    Pituitary; 2022 Dec; 25(6):795-809. PubMed ID: 36002784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.
    Kamenický P; Droumaguet C; Salenave S; Blanchard A; Jublanc C; Gautier JF; Brailly-Tabard S; Leboulleux S; Schlumberger M; Baudin E; Chanson P; Young J
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2796-804. PubMed ID: 21752886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osilodrostat oral tablets for adults with Cushing's disease.
    Martino M; Aboud N; Lucchetti B; Salvio G; Arnaldi G
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):99-109. PubMed ID: 35220871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cushing's disease: adrenal steroidogenesis inhibitors.
    Pivonello R; Simeoli C; Di Paola N; Colao A
    Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease.
    Pivonello R; Fleseriu M; Newell-Price J; Shimatsu A; Feelders RA; Kadioglu P; Tabarin A; Brue TC; Geer EB; Piacentini A; Pedroncelli AM; Biller BMK
    J Endocrinol Invest; 2024 Oct; 47(10):2437-2448. PubMed ID: 38696122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approach to the Patient Treated with Steroidogenesis Inhibitors.
    Castinetti F; Nieman LK; Reincke M; Newell-Price J
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease.
    Dougherty JA; Desai DS; Herrera JB
    Ann Pharmacother; 2021 Aug; 55(8):1050-1060. PubMed ID: 33143437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension.
    Gadelha M; Snyder PJ; Witek P; Bex M; Belaya Z; Turcu AF; Feelders RA; Heaney AP; Paul M; Pedroncelli AM; Auchus RJ
    Front Endocrinol (Lausanne); 2023; 14():1236465. PubMed ID: 37680892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.